Researchers reviewed medical studies considering the bone health of postmenopausal breast cancer patients.
Two large medical trials that evaluated the use of tamoxifen for breast cancer prevention found that it was not associated with an increase of fractures. However, these recent findings were especially true for women who received chemotherapy or were treated with specific drugs called aromatase inhibitors � including anastrozole, letrozole and exemestane, all of which have been associated with changes in bone mineral density.
Specifically, anastrozole treatment was associated with a 60 percent higher fracture risk than tamoxifen treatment.
While further interactions between bone density and cancer treatments are investigated, researchers recommend all postmenopausal women be monitored for osteoporosis.
All research on this web site is the property of Leslie Beck Nutrition Consulting Inc. and is protected by copyright. Keep in mind that research on these matters continues daily and is subject to change. The information presented is not intended as a substitute for medical treatment. It is intended to provide ongoing support of your healthy lifestyle practices.